おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
GluBio Therapeutics
company
About
GluBio Therapeutics engages in molecular glue-targeted protein degradation drug discovery.
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $50M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2021
- Operating Status
- Active
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$50M
GluBio Therapeutics has raised a total of
$50M
in funding over 2 rounds. Their latest funding was raised on
Feb 28, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 28, 2022 | Series A | $50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
GluBio Therapeutics is funded by 1 investors.
Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Lilly Asia Ventures
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
